Abstract/Journal Article

DZNE-2025-01481

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The Economic Burden of Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Dementia: Excess Costs and Associated Clinical and Risk Factors

Glaeser, E. (First author)DZNE* ; Kilimann, I.DZNE* ; Platen, M.DZNE* ; Hoffmann, W.DZNE* ; Brosseron, F.DZNE* ; Bürger, K.DZNE* ; Coenjaerts, M.DZNE* ; Düzel, E.DZNE* ; Ewers, M.DZNE* ; Fließbach, K.DZNE* ; Frommann, I.Extern* ; Gemenetzi, M.Extern* ; Glanz, W.DZNE* ; Hellmann-Regen, J.DZNE* ; Incesoy, E. I.DZNE* ; Janowitz, D.Extern* ; Jessen, F.DZNE* ; Peters, O.DZNE* ; Priller, J.DZNE* ; Ramirez, A.DZNE* ; Schneider, A.DZNE* ; Spottke, A.DZNE* ; Spruth, E. J.DZNE* ; Teipel, S.DZNE* ; Wagner, M.DZNE* ; Michalowsky, B. (Last author)DZNE* ; delcode (Collaboration Author)

2025

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz70860_100774

Abstract: This study assessed costs and cost-associated factors in patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and Alzheimer's Disease (AD) dementia compared to healthy controls.Clinical data, risk factors, healthcare resource use and informal care provision were assessed in the DELCODE study. Costs were calculated from payer and societal perspectives, with multivariate regression analyses identifying cost-associated factors.Societal costs were elevated by 50% for SCD (adjusted mean 7,705€ [95%CI 6,227-9,182€)], 199% for MCI (15,328€ [6,121-24,535€]) and 602% for AD (36,031€ [3,075-68,986€]) compared to controls (5,129€ [3,217-7,042€]). ApoE ε4 negative patients showed higher costs compared to positive patients. Hypertension was associated with higher costs, while lower education status and high cholesterol reduced costs.Healthcare costs are already significantly elevated in early subjective and objective cognitive impairment, driven by formal and informal care. The study emphasizes the importance of early interventions to reduce the economic burden and delay progression.

Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Cognitive Dysfunction: economics (MeSH) ; Alzheimer Disease: economics (MeSH) ; Aged (MeSH) ; Health Care Costs: statistics & numerical data (MeSH) ; Public Health: economics (MeSH) ; Risk Factors (MeSH) ; Cost of Illness (MeSH) ; Aged, 80 and over (MeSH) ; Middle Aged (MeSH)

---

Contributing Institute(s):

1. Patient-Reported Outcomes and Health Economics Research (AG Michalowsky)
2. Translational Health Care Research (AG Hoffmann)
3. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
4. Neuropsychology (AG Wagner)
5. Clinical Alzheimer’s Disease Research (AG Jessen)
6. Neuroinflammation, Biomarker (AG Heneka)
7. Clinical Research (Munich) (Clinical Research (Munich))
8. Clinical Neurophysiology and Memory (AG Düzel)
9. Patient Studies (Bonn) (Patient Studies (Bonn))
10. Interdisciplinary Dementia Research (AG Endres)
11. Biomarker-Assisted Early Detection of Dementias (AG Peters)
12. Translational Neuropsychiatry (AG Priller)
13. Translational Dementia Research (Bonn) (AG Schneider)
14. Clinical Research Platform (CRP) (AG Spottke)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Experiment(s):

1. Longitudinal Cognitive Impairment and Dementia Study

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---